2014
Founded
$225M+
Funding
87%
DILI Sensitivity
FDA
ISTAND Qualified
COMPANY OVERVIEW
Emulate is the global leader in organ-on-chip technology, spun out of the Wyss Institute at Harvard University. In September 2024, their Liver-Chip became the first organ-chip to receive FDA ISTAND (Innovative Science and Technology Approaches for New Drugs) qualification for predicting drug-induced liver injury (DILI).
PRODUCTS
LIVER-CHIP
DILI Prediction
FDA ISTAND qualified. 87% sensitivity, 100% specificity for hepatotoxicity.
LUNG-CHIP
Respiratory
Alveolus-chip for respiratory disease and inhalation toxicology.
INTESTINE-CHIP
Gut Barrier
Intestinal absorption and gut-liver axis studies.
BRAIN-CHIP
BBB Model
Blood-brain barrier chip for CNS drug delivery.
KEY MILESTONES
- 2014 - Spun out of Wyss Institute at Harvard
- 2017 - First commercial Organ-Chip launch
- 2022 - FDA Modernization Act passes, enabling non-animal testing
- 2024 - FDA ISTAND qualification for Liver-Chip (September)